After Weighting, 3.6 Million Likely to Be Newly Eligible for Semaglutide
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 26, 2024 -- Increases in eligibility for semaglutide are discussed in a research letter published online Aug. 27 in the Annals of Internal Medicine.
After the Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity trial showed that semaglutide reduced cardiovascular events in certain patients without diabetes, Medicare announced it would allow Part D to cover semaglutide. Alexander Chaitoff, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues identified Medicare beneficiaries most likely to be newly eligible for semaglutide and estimated the maximum costs to Part D.
The researchers found that overall, 5,111 Medicare-eligible adults (about 61 percent) with complete data had a body mass index (BMI) of 27 kg/m2 or more. After weighting, 3.6 million people (14.2 percent) were highly likely to be newly eligible for semaglutide; this number could increase to 15.2 million people (60.9 percent) using more liberal definitions of established cardiovascular disease (CVD). Maximum Medicare spending could be an additional $34 to $145 billion annually if all newly eligible beneficiaries received semaglutide. The demographics of newly eligible patients will depend on the definition of established CVD, but younger, generally healthier, female Medicare beneficiaries are likely to remain ineligible.
"Although approximately one in seven Medicare beneficiaries with elevated BMI is likely to be newly eligible for semaglutide, the majority will remain ineligible if a narrow definition of established CVD is used by Part D plans," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy...
Increased Risk for CVD Seen for Women With Premenstrual Disorders
THURSDAY, July 17, 2025 -- Women with premenstrual disorders (PMDs) have an increased risk for cardiovascular diseases (CVDs), according to a study published online July 11 in...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.